The Kable

The Kable

Share this post

The Kable
The Kable
💊 Novavax exits Gavi deal; Telangana’s Pharma City builds on farmer lands; Have you had your tea yet?
Copy link
Facebook
Email
Notes
More

💊 Novavax exits Gavi deal; Telangana’s Pharma City builds on farmer lands; Have you had your tea yet?

#222 | GSK laying off staff in India

Vinod's avatar
Vinod
Nov 23, 2022
∙ Paid

Share this post

The Kable
The Kable
💊 Novavax exits Gavi deal; Telangana’s Pharma City builds on farmer lands; Have you had your tea yet?
Copy link
Facebook
Email
Notes
More
Share

Hello, and welcome back to The Kable. Research says Wednesdays are the best days to work on your CV. Especially if you're working with GSK in India. Even more so if you are among the 150 people being let go.

Yesterday the WHO said it is preparing a list of pathogens that can cause the next pandemic. The US National Institute of Allergy and Infectious Diseases is going one-up by awarding three institutions more than $12 million to develop antiviral therapies to treat diseases caused by pandemicky viruses.

In what has already been a record year for expensive gene therapies, a new haemophilia treatment has gotten the US FDA's nod. And this particular gene therapy is priced at $3.5 million. Money? What is money anymore?

And finally, the WHO has been mulling a name change for monkeypox for a while now to avoid any stigma. The agency is settling on MPOX as the new name.

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 The Kable
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More